Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.70 USD
Change Today -0.14 / -4.93%
Volume 400.0
RESX On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

restorgenex corp (RESX) Snapshot

Open
$2.80
Previous Close
$2.84
Day High
$2.80
Day Low
$2.70
52 Week High
04/28/14 - $5.50
52 Week Low
03/26/15 - $2.35
Market Cap
50.3M
Average Volume 10 Days
1.5K
EPS TTM
$-0.72
Shares Outstanding
18.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RESTORGENEX CORP (RESX)

Related News

No related news articles were found.

restorgenex corp (RESX) Related Businessweek News

No Related Businessweek News Found

restorgenex corp (RESX) Details

RestorGenex Corporation operates as a specialty biopharmaceutical company that focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product is a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company’s pipeline also includes a “soft” anti-androgen compound for the treatment of acne vulgaris. The company was formerly known as Stratus Media Group, Inc. and changed its name to RestorGenex Corporation in March 2014. RestorGenex Corporation is headquartered in Buffalo Grove, Illinois.

8 Employees
Last Reported Date: 04/3/15

restorgenex corp (RESX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $562.3K
Chief Financial Officer and Secretary
Total Annual Compensation: $287.7K
Executive Vice President of Preclinical Devel...
Total Annual Compensation: $358.9K
Senior Vice President of Clinical Development
Total Annual Compensation: $220.9K
Compensation as of Fiscal Year 2014.

restorgenex corp (RESX) Key Developments

RestorGenex Corporation Reports Earnings Results for the Year Ended December 31, 2014

RestorGenex Corporation reported earnings results for the year ended December 31, 2014. The company incurred a net loss of approximately $14.4 million or $1.00 per share for the year ended December 31, 2014, compared to a net loss of $2.6 million or $1.00 per share for 2013. The increase in the net loss was due primarily to higher expenses in 2014 associated with the company's research and development efforts to advance its technologies and products and an impairment of intangible assets. The company has no debt.

Restorgenex Corporation Provides Earnings Guidance for the Year Ended December 31, 2014

Restorgenex Corporation provided earnings guidance for the year ended December 31, 2014. The company anticipated that its reported net loss will be approximately $14.4 million or $1.01 per share for the year ended December 31, 2014, compared to a net loss of $2.6 million or $1.00 per share for 2013. The increase in the net loss is due primarily to higher expenses in 2014 associated with the company's research and development efforts to advance its technologies and products and an impairment of intangible assets.

Restorgenex Corporation announced delayed annual 10-K filing

On 03/31/2015, Restorgenex Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RESX:US $2.70 USD -0.14

RESX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RESX.
View Industry Companies
 

Industry Analysis

RESX

Industry Average

Valuation RESX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESTORGENEX CORP, please visit www.stratusmediagroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.